Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Perrone

Showing results (31-40 of 272) with videos related to

Pageof 28
Sort By:
JAMA Oncology|November 11, 2016
A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right ChoiceFrancesco Perrone, Massimo Di Maio, Lucia Del Mastro
Current Opinion in Oncology|February 24, 2005
Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trialsFrancesco Perrone, Massimo Di Maio, Alfredo Budillon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast CancerMatteo Lambertini, Eva Blondeaux, Francesco Perrone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES)Francesco Perrone, Massimo Di Maio, Ciro Gallo, et al.
Journal of the National Cancer Institute|October 30, 2008
Re: Design and endpoints of clinical trials in hepatocellular carcinomaMassimo Di Maio, Bruno Daniele, Ciro Gallo, et al.
Current Drug Targets|March 31, 2012
Conventional chemotherapy of advanced pancreatic cancerFrancesco Giuliani, Massimo Di Maio, Giuseppe Colucci, et al.
Nature Reviews. Clinical Oncology|January 21, 2016
Patient-reported outcomes in the evaluation of toxicity of anticancer treatmentsMassimo Di Maio, Ethan Basch, Jane Bryce, et al.
Nature Clinical Practice. Oncology|March 8, 2006
Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?Massimo Di Maio, Cesare Gridelli, Ciro Gallo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2004
Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?Nicola Normanno, Massimo Di Maio, Francesco Perrone, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|October 25, 2014
A meta-analysis of the impact of bronchial stump coverage on the risk of bronchopleural fistula after pneumonectomyMassimo Di Maio, Francesco Perrone, Claude Deschamps, et al.
Pageof 28

Showing results (31-40 of 272) with videos related to

Sort By:
Pageof 28
JAMA Oncology|November 11, 2016
A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right ChoiceFrancesco Perrone, Massimo Di Maio, Lucia Del Mastro
Current Opinion in Oncology|February 24, 2005
Targeted therapies and non-small cell lung cancer: methodological and conceptual challenge for clinical trialsFrancesco Perrone, Massimo Di Maio, Alfredo Budillon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2019
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast CancerMatteo Lambertini, Eva Blondeaux, Francesco Perrone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2004
Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES)Francesco Perrone, Massimo Di Maio, Ciro Gallo, et al.
Journal of the National Cancer Institute|October 30, 2008
Re: Design and endpoints of clinical trials in hepatocellular carcinomaMassimo Di Maio, Bruno Daniele, Ciro Gallo, et al.
Current Drug Targets|March 31, 2012
Conventional chemotherapy of advanced pancreatic cancerFrancesco Giuliani, Massimo Di Maio, Giuseppe Colucci, et al.
Nature Reviews. Clinical Oncology|January 21, 2016
Patient-reported outcomes in the evaluation of toxicity of anticancer treatmentsMassimo Di Maio, Ethan Basch, Jane Bryce, et al.
Nature Clinical Practice. Oncology|March 8, 2006
Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?Massimo Di Maio, Cesare Gridelli, Ciro Gallo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2004
Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?Nicola Normanno, Massimo Di Maio, Francesco Perrone, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|October 25, 2014
A meta-analysis of the impact of bronchial stump coverage on the risk of bronchopleural fistula after pneumonectomyMassimo Di Maio, Francesco Perrone, Claude Deschamps, et al.
Pageof 28